© Copyright RiverVest® All Rights Reserved.
/ PORTFOLIO
Branford, CT
CGI Pharmaceuticals discovered and generated a library of small molecules with a focus on kinase biology. The lead preclinical compound targeted spleen tyrosine kinase (SyK) with potential applications in the treatment of serious inflammatory diseases, including rheumatoid arthritis.
Acquired by Gilead Sciences, Inc. in July 2017.